{"entity":{"id":"nct03498326","kind":"trial","name":"Gemcitabine and Celecoxib Combination Therapy in Treating Patients With R0 Resection Pancreatic Cancer","aka":["GCRP"],"tldr":"A phase 2 trial of gemcitabine in pancreatic cancer, run by Second Affiliated Hospital, Zhejiang University, School of Medicine, now recruiting.","summary":"Gemcitabine and Celecoxib Combination Therapy in Treating Patients With R0 Resection Pancreatic Cancer is a phase 2, randomised interventional study registered as NCT03498326 by Second Affiliated Hospital, Zhejiang University, School of Medicine, with a registry enrolment figure of 480 participants, started 2018-04-02 and due to reach its primary completion in 2023-03-31. Interventions recorded: Gemcitabine; Gemcitabine. Conditions listed: Pancreatic Cancer; Chemotherapy Effect. Primary outcome: disease free survival. Pancreatic eligibility wording from the registry: \"Endocrine carcinoma, acinar pancreatic carcinoma, or cystadenocarcinoma (cystadenocarcinoma)\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT03498326","url":"https://clinicaltrials.gov/study/NCT03498326"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["gemcitabine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03498326","phase":"2","setting":"Gemcitabine and Celecoxib Combination Therapy in Treating Patients With R0 Resection Pancreatic Cancer","sponsor":"Second Affiliated Hospital, Zhejiang University, School of Medicine","participation":[{"nct":"NCT03498326","source":"https://clinicaltrials.gov/study/NCT03498326","fetchedAt":"2026-10-07T16:53:03.448Z","studySha256":"a1423e768fe65a508cb9f323557114bd80e2b1dead5fc06d5ed160da9e2929e2","overallStatus":"RECRUITING","lastUpdatePosted":"2018-05-30","leadSponsor":"Second Affiliated Hospital, Zhejiang University, School of Medicine","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"90 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":480,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2018-04-02","startedType":"actual","enrolled":480,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03498326/","neighbours":{"cancer":[{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}